THE COMPARISON OF LENOGRASTIM AND FILGRASTIM IN ALLOGENE?C STEM CELL TRANSPLANTAT?ON: EFFECTS ON BONE MARROW STEM CELL PR?M?NG
(Abstract release date: 05/21/15)
EHA Library. Fettah A. 06/12/15; 102933; PB2046
Disclosure(s): Ankara Children's Hematology and Oncology Research Hospital, Pediatric Hematology and Bone Marrow transplantation UnitPediatric Hematology Department
Ali Fettah
Contributions
Contributions
Abstract
Abstract: PB2046
Type: Publication Only
Background
Hematopoietic stem cell transplantation from HLA-matched siblings improved long-term survival of the children with hematologic malignancies and bone marrow failure syndromes.Recombinant human granulocyte colony stimulating factor (G-CSF) is used to mobilize hematopoietic stem cells for allogeneic and autologous hematopoieitc stem cell transplantation.
Aims
In this study, we aimed to compare the efficacy profile of different G-CSF agents including biosimilar filgrastim (Leucostim®) and lenograstim (Granocyte®) on bone marrow stem cell mobilization in healthy donors
Methods
A total of 29 healthy donors were enrolled in the study and analysed retrospectively. Fifteen donors received biosimilar filgrastim and fourteen donors received lenograstim. The dose and duration of G-CSF treatment was 10 ?cgr/kg/dose for 3 days and similar between two groups. Post-G-CSF white blood cells, harvested stem cell volume, number of total nucleated cells (TNC) and CD34+ cells, CFU-GM colony number has been compared between biosimilar filgrastim and lenograstim groups.
Results
There were 16 (55.2%) male and 13 (44.8%) female donors. The median age and body weight of donors was 12.5±10.2 years and 37.1±19.3 kg respectively. The median number of post G-CSF white blood cells (x103/?L) [32.6 (28-41.2) vs. 37.3 (25.7-40), p=0.663], harvested total stem cell volume (cc) [437 (385-850) vs. 643 (324-1018), p=0.694], number of total nucleated cells(x108/recipient kg) [6.4 (5.1-8.7) vs. 7.1 (5.1-8.6), p=0.861], CD34+ cells (?L) in the harvested stem cell [183 (104-272) vs. 160 (93-259), p=0.801], number of CD34+ cells (x106/recipient kg) [3.1 (2.1-5.2) vs. 2.6 (2.3-5.5), p=0.930], CFU-GM colony number (x104/recipient kg) [13.2 (8-15.4) vs. 14.1 (9.8-25.6), p=0.538] were similar between filgrastim and lenograstim groups.
Summary
In conclusion, the current retrospective study shows that biosimilar filgrastim and lenograstim are similar in terms of efficacy for the mobilization of bone marrow hematopoietic stem cells in healthy donors.
Keyword(s): Allogeneic hematopoietic stem cell transplant, Children, G-CSF, Stem cell mobilization
Session topic: Publication Only
Type: Publication Only
Background
Hematopoietic stem cell transplantation from HLA-matched siblings improved long-term survival of the children with hematologic malignancies and bone marrow failure syndromes.Recombinant human granulocyte colony stimulating factor (G-CSF) is used to mobilize hematopoietic stem cells for allogeneic and autologous hematopoieitc stem cell transplantation.
Aims
In this study, we aimed to compare the efficacy profile of different G-CSF agents including biosimilar filgrastim (Leucostim®) and lenograstim (Granocyte®) on bone marrow stem cell mobilization in healthy donors
Methods
A total of 29 healthy donors were enrolled in the study and analysed retrospectively. Fifteen donors received biosimilar filgrastim and fourteen donors received lenograstim. The dose and duration of G-CSF treatment was 10 ?cgr/kg/dose for 3 days and similar between two groups. Post-G-CSF white blood cells, harvested stem cell volume, number of total nucleated cells (TNC) and CD34+ cells, CFU-GM colony number has been compared between biosimilar filgrastim and lenograstim groups.
Results
There were 16 (55.2%) male and 13 (44.8%) female donors. The median age and body weight of donors was 12.5±10.2 years and 37.1±19.3 kg respectively. The median number of post G-CSF white blood cells (x103/?L) [32.6 (28-41.2) vs. 37.3 (25.7-40), p=0.663], harvested total stem cell volume (cc) [437 (385-850) vs. 643 (324-1018), p=0.694], number of total nucleated cells(x108/recipient kg) [6.4 (5.1-8.7) vs. 7.1 (5.1-8.6), p=0.861], CD34+ cells (?L) in the harvested stem cell [183 (104-272) vs. 160 (93-259), p=0.801], number of CD34+ cells (x106/recipient kg) [3.1 (2.1-5.2) vs. 2.6 (2.3-5.5), p=0.930], CFU-GM colony number (x104/recipient kg) [13.2 (8-15.4) vs. 14.1 (9.8-25.6), p=0.538] were similar between filgrastim and lenograstim groups.
Summary
In conclusion, the current retrospective study shows that biosimilar filgrastim and lenograstim are similar in terms of efficacy for the mobilization of bone marrow hematopoietic stem cells in healthy donors.
Keyword(s): Allogeneic hematopoietic stem cell transplant, Children, G-CSF, Stem cell mobilization
Session topic: Publication Only
Abstract: PB2046
Type: Publication Only
Background
Hematopoietic stem cell transplantation from HLA-matched siblings improved long-term survival of the children with hematologic malignancies and bone marrow failure syndromes.Recombinant human granulocyte colony stimulating factor (G-CSF) is used to mobilize hematopoietic stem cells for allogeneic and autologous hematopoieitc stem cell transplantation.
Aims
In this study, we aimed to compare the efficacy profile of different G-CSF agents including biosimilar filgrastim (Leucostim®) and lenograstim (Granocyte®) on bone marrow stem cell mobilization in healthy donors
Methods
A total of 29 healthy donors were enrolled in the study and analysed retrospectively. Fifteen donors received biosimilar filgrastim and fourteen donors received lenograstim. The dose and duration of G-CSF treatment was 10 ?cgr/kg/dose for 3 days and similar between two groups. Post-G-CSF white blood cells, harvested stem cell volume, number of total nucleated cells (TNC) and CD34+ cells, CFU-GM colony number has been compared between biosimilar filgrastim and lenograstim groups.
Results
There were 16 (55.2%) male and 13 (44.8%) female donors. The median age and body weight of donors was 12.5±10.2 years and 37.1±19.3 kg respectively. The median number of post G-CSF white blood cells (x103/?L) [32.6 (28-41.2) vs. 37.3 (25.7-40), p=0.663], harvested total stem cell volume (cc) [437 (385-850) vs. 643 (324-1018), p=0.694], number of total nucleated cells(x108/recipient kg) [6.4 (5.1-8.7) vs. 7.1 (5.1-8.6), p=0.861], CD34+ cells (?L) in the harvested stem cell [183 (104-272) vs. 160 (93-259), p=0.801], number of CD34+ cells (x106/recipient kg) [3.1 (2.1-5.2) vs. 2.6 (2.3-5.5), p=0.930], CFU-GM colony number (x104/recipient kg) [13.2 (8-15.4) vs. 14.1 (9.8-25.6), p=0.538] were similar between filgrastim and lenograstim groups.
Summary
In conclusion, the current retrospective study shows that biosimilar filgrastim and lenograstim are similar in terms of efficacy for the mobilization of bone marrow hematopoietic stem cells in healthy donors.
Keyword(s): Allogeneic hematopoietic stem cell transplant, Children, G-CSF, Stem cell mobilization
Session topic: Publication Only
Type: Publication Only
Background
Hematopoietic stem cell transplantation from HLA-matched siblings improved long-term survival of the children with hematologic malignancies and bone marrow failure syndromes.Recombinant human granulocyte colony stimulating factor (G-CSF) is used to mobilize hematopoietic stem cells for allogeneic and autologous hematopoieitc stem cell transplantation.
Aims
In this study, we aimed to compare the efficacy profile of different G-CSF agents including biosimilar filgrastim (Leucostim®) and lenograstim (Granocyte®) on bone marrow stem cell mobilization in healthy donors
Methods
A total of 29 healthy donors were enrolled in the study and analysed retrospectively. Fifteen donors received biosimilar filgrastim and fourteen donors received lenograstim. The dose and duration of G-CSF treatment was 10 ?cgr/kg/dose for 3 days and similar between two groups. Post-G-CSF white blood cells, harvested stem cell volume, number of total nucleated cells (TNC) and CD34+ cells, CFU-GM colony number has been compared between biosimilar filgrastim and lenograstim groups.
Results
There were 16 (55.2%) male and 13 (44.8%) female donors. The median age and body weight of donors was 12.5±10.2 years and 37.1±19.3 kg respectively. The median number of post G-CSF white blood cells (x103/?L) [32.6 (28-41.2) vs. 37.3 (25.7-40), p=0.663], harvested total stem cell volume (cc) [437 (385-850) vs. 643 (324-1018), p=0.694], number of total nucleated cells(x108/recipient kg) [6.4 (5.1-8.7) vs. 7.1 (5.1-8.6), p=0.861], CD34+ cells (?L) in the harvested stem cell [183 (104-272) vs. 160 (93-259), p=0.801], number of CD34+ cells (x106/recipient kg) [3.1 (2.1-5.2) vs. 2.6 (2.3-5.5), p=0.930], CFU-GM colony number (x104/recipient kg) [13.2 (8-15.4) vs. 14.1 (9.8-25.6), p=0.538] were similar between filgrastim and lenograstim groups.
Summary
In conclusion, the current retrospective study shows that biosimilar filgrastim and lenograstim are similar in terms of efficacy for the mobilization of bone marrow hematopoietic stem cells in healthy donors.
Keyword(s): Allogeneic hematopoietic stem cell transplant, Children, G-CSF, Stem cell mobilization
Session topic: Publication Only
{{ help_message }}
{{filter}}